Abstract:OBJECTIVE:To confirm the non-inferiority of the IOP-lowering effect of the 0.0015% Tafluprost ophthalmic solution to the 0.005% Latanoprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.Safety was also compared between two groups.METHODS:This study was conducted from August 2008 to December 2009, at five clinical trial sites in China. Patients of this study population was diagnosed with primary open-angle glaucoma or ocular hypertension in both eyes.Subjects were randomized into 0.0015% Tafluprost group or 0.005% Latanoprost group.Intraocular pressure (IOP) measurement by Goldmann applanation tonometer, slit-lamp microscopy, Gonioscopy, Fundascopy, Visual acuity test, Perimetry, Blood pressure and pulse rate, Subjective symptoms were compered between two groups at Week 0, Week 2 and Week 4.For main effectiveness evaluation index adopt the bad effect evaluation, safety evaluation index by Fisher's exact test probability method.RESULTS:The 246 subjects/246 eyes were randomized (Tafluprost group:122 subjects/122 eyes, Latanoprost group:124 subjects/ 124 eyes). Change in the IOP at 17:00 of Week 2 is (8.8 ± 3.8) mmHg and (8.9 ± 4.4) mmHg (1 mmHg = 0.133 kPa) in Tafluprost group and Latanoprost group. Percent change in the IOP at 17:00 of Week 2 is (33.2 ± 12.8)% and (34.4 ± 14.1)% in Tafluprost group and Latanoprost group. Change in the IOP at 17:00 at the end of treatment is (9.8 ± 4.0) mmHg and (9.2 ± 4.1) mmHg in Tafluprost group and Latanoprost group. Percent change in the IOP at 17:00 at the end of treatment is 37.2% ± 13.4% group and 35.7% ± 13.0% in Tafluprost and Latanoprost group.In addition, distribution of subjects with percentage decrease of IOP > 30% was 72.5% in Tafluprost group higher than 63.8% in Latanoprost group. The major adverse reactions were conjunctival hyperemia, eye irritation, eye pain and foreign body sensation. The incidence of adverse reactions is 31.7% in Tafluprost group and 20.8% in Latanoprost group. The inter-group difference had no statistical significance.CONCLUSION:Efficacy and safety of Tafluprost ophthalmic solution are no less than Latanoprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.

A Comparison of the Ocular Hypotensive Efficacy of Three Prostaglandin Analogs

Comparison of Intraocular Pressure Reducing Effects of Three Prostaglandin Eyedrops in Open-Angle Glaucoma

Comparison of Latanoprost and Brimonidine in the Treatment of Open Angle Glaucoma

A Meta-Analysis of Therapy Comparison Between Bimatoprost and Timolol in Ocular Hypertention Eye

Intraocular Pressure Lowering Efficacy and Safety of Travoprost 0.004% As A Replacement Therapy in Patients with Open Angle Glaucoma or Ocular Hypertension

Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.

Intraocular Pressure-Lowering Efficacy and Safety of Bimatoprost 0.03% Therapy for Primary Open-Angle Glaucoma and Ocular Hypertension Patients in China.

Timolol,brinzolamide and Travoprost in Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension

[Randomized Parallel Group Study of 0.0015% Tafluprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension (comparison with 0.005% Latanoprost Ophthalmic Solution)].

Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma.

Latanoprost-induced stabilization of central visual function in patients with primary open-angle glaucoma

Comparison of a preservative‐free bimatoprost 0.01% ophthalmic gel with a preserved bimatoprost 0.01% ophthalmic solution: A phase III, randomized, multicentre, 3‐month study

Efficacy and safety of bimatoprost 0.03% in patients with elevated intraocular pressure: a comparison with latanoprost 0.005%

A 12-Week, Double-Masked, Parallel-Group Study of the Safety and Efficacy of Travoprost 0.004% Compared with Pilocarpine 1% in Chinese Patients with Primary Angle-Closure and Primary Angle-Closure Glaucoma

24-Hour efficacy of single primary selective laser trabeculoplasty versus latanoprost eye drops for Naïve primary open-angle glaucoma and ocular hypertension patients

Meta-analysis of the Efficacy and Safety of Latanoprost Monotherapy in Patients With Angle-closure Glaucoma.

Comparability of Three Intraocular Pressure Measurement: Icare Pro Rebound, Non-Contact and Goldmann Applanation Tonometry in Different IOP Group.

Efficacy and Safety of Travoprost Versus Timolol to Treat Early-Onset Ocular Hypertension Secondary to Vitrectomy: A Randomized Trial

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Efficacy of Morning Versus Evening Latanoprost/Timolol Fixed Combination for Open-Angle Glaucoma and Ocular Hypertension: A Randomized Clinical Trial

Preservative-free Bimatoprost 0.01% Ophthalmic Gel for Glaucoma Therapy. A Phase III Randomized Controlled Trial